

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA Selinexor with bortezomib and low-dose dexamethasone for relapsed or refractory multiple myeloma [ID3797]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

No potential equality issues were identified during scoping. However, stakeholders highlighted that multiple myeloma is more common in men, older people ( $\geq 75$  years) and people from African or Caribbean ethnic groups.

The committee considered that the recommendations apply equally to all people with relapsed or refractory multiple myeloma, regardless of sex, age and ethnicity. It concluded that the difference in prevalence did not represent an equality issue in this evaluation.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not relevant.

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Section 3.20 of the draft guidance.

**Approved by Associate Director (name):** Emily Crowe...

**Date:** 24/01/2024